HealthInvest Partners AB
Latest statistics and disclosures from Atle Fund Management AB's latest quarterly 13F-HR filing:
- Top 5 stock holdings are LLY, ABBV, MRK, TMO, NBIX, and represent 34.95% of Atle Fund Management AB's stock portfolio.
- Added to shares of these 10 stocks: CVS (+$8.5M), IONS (+$7.3M), INCY (+$7.0M), INSM, ABVX, ABBV, MRK, IDYA, CMPX, ONC.
- Started 8 new stock positions in IDYA, INCY, INSM, CMPX, IONS, PYXS, CVS, ABVX.
- Reduced shares in these 10 stocks: LLY (-$6.6M), GILD, BBIO, KRYS, COR, BCAX, CAH, NBIX, DXCM, CRBP.
- Sold out of its positions in RNA, EW, HRMY, JANX, MREO, SMMT, MRUS.
- Atle Fund Management AB was a net buyer of stock by $41M.
- Atle Fund Management AB has $313M in assets under management (AUM), dropping by 1062.23%.
- Central Index Key (CIK): 0001381843
Tip: Access up to 7 years of quarterly data
Positions held by HealthInvest Partners AB consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Atle Fund Management AB
Atle Fund Management AB holds 39 positions in its portfolio as reported in the December 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Eli Lilly & Co. (LLY) | 10.7 | $34M | -16% | 31k | 1074.68 |
|
| Abbvie (ABBV) | 7.9 | $25M | +17% | 108k | 228.49 |
|
| Merck & Co (MRK) | 6.6 | $21M | +21% | 196k | 105.26 |
|
| Thermo Fisher Scientific (TMO) | 5.5 | $17M | +10% | 30k | 579.45 |
|
| Neurocrine Biosciences (NBIX) | 4.3 | $13M | -7% | 95k | 141.83 |
|
| Intuitive Surgical Com New (ISRG) | 4.0 | $13M | +13% | 22k | 566.36 |
|
| Beone Medicines Ltd- Sponsored Ads (ONC) | 3.9 | $12M | +33% | 40k | 303.81 |
|
| Bridgebio Pharma (BBIO) | 3.4 | $11M | -19% | 141k | 76.49 |
|
| Vertex Pharmaceuticals Incorporated (VRTX) | 3.3 | $10M | +29% | 23k | 453.36 |
|
| Boston Scientific Corporation (BSX) | 3.3 | $10M | +25% | 109k | 95.35 |
|
| Stryker Corporation (SYK) | 3.0 | $9.4M | +17% | 27k | 351.47 |
|
| CVS Caremark Corporation (CVS) | 2.7 | $8.5M | NEW | 107k | 79.36 |
|
| Krystal Biotech (KRYS) | 2.7 | $8.3M | -19% | 34k | 246.54 |
|
| AmerisourceBergen (COR) | 2.6 | $8.0M | -16% | 24k | 337.75 |
|
| Ionis Pharmaceuticals (IONS) | 2.3 | $7.3M | NEW | 92k | 79.11 |
|
| Revolution Medicines (RVMD) | 2.3 | $7.2M | +5% | 90k | 79.65 |
|
| Amgen (AMGN) | 2.3 | $7.2M | +58% | 22k | 327.31 |
|
| Mirum Pharmaceuticals (MIRM) | 2.3 | $7.1M | -4% | 90k | 78.99 |
|
| Incyte Corporation (INCY) | 2.2 | $7.0M | NEW | 71k | 98.77 |
|
| NewAmsterdam Pharma Co NV Ordinary Shares (NAMS) | 2.2 | $6.9M | 197k | 35.08 |
|
|
| Alkermes SHS (ALKS) | 2.2 | $6.8M | -4% | 243k | 27.98 |
|
| Irhythm Technologies (IRTC) | 2.1 | $6.7M | +25% | 38k | 177.44 |
|
| Gilead Sciences (GILD) | 2.0 | $6.2M | -35% | 51k | 122.74 |
|
| UFP Technologies (UFPT) | 1.6 | $5.1M | 23k | 222.03 |
|
|
| Insmed Com Par $.01 (INSM) | 1.5 | $4.9M | NEW | 28k | 174.04 |
|
| Cardinal Health (CAH) | 1.5 | $4.8M | -22% | 24k | 205.50 |
|
| Abivax Sa Sponsored Ads (ABVX) | 1.4 | $4.3M | NEW | 32k | 134.85 |
|
| Celcuity (CELC) | 1.3 | $4.2M | +12% | 42k | 99.74 |
|
| Disc Medicine (IRON) | 1.2 | $3.8M | +4% | 48k | 79.41 |
|
| Ideaya Biosciences (IDYA) | 1.1 | $3.4M | NEW | 97k | 34.57 |
|
| UnitedHealth (UNH) | 1.0 | $3.2M | +6% | 15k | 218.02 |
|
| Compass Therapeutics (CMPX) | 1.0 | $3.1M | NEW | 584k | 5.37 |
|
| Soleno Therapeutics (SLNO) | 0.9 | $2.9M | +4% | 63k | 46.30 |
|
| Arcellx Common Stock (ACLX) | 0.9 | $2.7M | +62% | 42k | 65.20 |
|
| Dexcom Com New (DXCM) | 0.8 | $2.6M | -21% | 40k | 66.37 |
|
| Autolus Therapeutics Spon Ads (AUTL) | 0.7 | $2.3M | 1.2M | 1.99 |
|
|
| Bicara Therapeutics (BCAX) | 0.6 | $1.9M | -45% | 111k | 16.83 |
|
| Corbus Pharmaceuticals Hldgs (CRBP) | 0.3 | $873k | -38% | 107k | 8.14 |
|
| Pyxis Oncology Common Stock (PYXS) | 0.2 | $710k | NEW | 617k | 1.15 |
|
Past Filings by Atle Fund Management AB
SEC 13F filings are viewable for Atle Fund Management AB going back to 2013
- Atle Fund Management AB 2025 Q4 filed Feb. 6, 2026
- Atle Fund Management AB 2025 Q3 filed Nov. 4, 2025
- Atle Fund Management AB 2025 Q2 filed July 14, 2025
- Atle Fund Management AB 2025 Q1 filed May 5, 2025
- HealthInvest Partners AB 2024 Q4 filed Feb. 4, 2025
- HealthInvest Partners AB 2024 Q3 filed Nov. 12, 2024
- HealthInvest Partners AB 2024 Q1 filed April 25, 2024
- HealthInvest Partners AB 2023 Q4 filed Jan. 30, 2024
- HealthInvest Partners AB 2022 Q4 filed Feb. 14, 2023
- HealthInvest Partners AB 2022 Q3 filed Oct. 21, 2022
- HealthInvest Partners AB 2022 Q2 filed July 8, 2022
- HealthInvest Partners AB 2022 Q1 filed May 5, 2022
- HealthInvest Partners AB 2021 Q4 filed Jan. 18, 2022
- HealthInvest Partners AB 2021 Q3 filed Nov. 8, 2021
- HealthInvest Partners AB 2021 Q2 filed Aug. 10, 2021
- HealthInvest Partners AB 2021 Q1 filed April 30, 2021